Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric.
The disease is characterized by hyperkeratotic, crusted or excoriated, light-red to bright-red papules, nodules or plaques with hyperpigmented margins as a distinguish features.
Prurigo Nodularis Epidemiological Segmentation
The Epidemiological Segmentation of Prurigo Nodularis in 7MM from 2017 to 2030 is segmented as:-
• Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalence
• Age-specific Diagnosed Prevalence
• Type-specific Diagnosed Prevalence
• Severity-specific Diagnosed Prevalence
Prurigo Nodularis Epidemiology
• The total diagnosed prevalent population in 7MM in 2017 was 539,893
• The United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases in 2017
• EU5 countries occupied 38.31% of the patient pool amongst 7MM in 2017
The market size of Prurigo Nodularis in 7MM in 2017 was USD 659.29 Million
Prurigo Nodularis Market Drivers
• Government Initiatives
• Pipeline Advancements and various off-label therapies
• Growth in R&D
• Increase in the number of patients
Prurigo Nodularis Market Barriers
• Disease-related challenges in terms of pathophysiology and management
• Lack of Clinical Trial Data
Prurigo Nodularis Emerging Drugs
The emerging drugs of the Prurigo Nodularis market are
• Serlopitant
• Nalbuphine ER
• Nemolizumab (CD14152)
• Apremilast (CC-10004)
• M 118103
• KPL-716
• Dupixent (Dupilumab/SAR231893)
And many others.
Prurigo Nodularis Key Players
The key players in the Prurigo Nodularis market are
• Menlo Therapeutics
• Trevi Therapeutics
• Galderma
• Amgen
• Maruho
• Kiniksa Pharmaceuticals
• Sanofi
• Regeneron Pharmaceuticals
And many others.